Back to Search
Start Over
Targeting properdin in the treatment of atypical haemolytic uraemic syndrome: better than eculizumab?
- Source :
-
Annals of translational medicine [Ann Transl Med] 2018 Nov; Vol. 6 (Suppl 1), pp. S62. - Publication Year :
- 2018
-
Abstract
- Competing Interests: Conflicts of Interest: KJ Marchbank is a member of Gemini Therapeutics inc scientific advisor board and is contracted by Idorsia ltd to test agents in the C3 GOF mouse. K Smith-Jackson has no conflicts of interest to declare.
Details
- Language :
- English
- ISSN :
- 2305-5839
- Volume :
- 6
- Issue :
- Suppl 1
- Database :
- MEDLINE
- Journal :
- Annals of translational medicine
- Publication Type :
- Editorial & Opinion
- Accession number :
- 30613637
- Full Text :
- https://doi.org/10.21037/atm.2018.10.35